- Home
- NAGE vs GERN Comparison
NAGE vs GERN Comparison
Compare NAGE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAGE
- GERN
- Stock Information
- Founded
- NAGE 1999
- GERN 1990
- Country
- NAGE United States
- GERN United States
- Employees
- NAGE N/A
- GERN N/A
- Industry
- NAGE Medicinal Chemicals and Botanical Products
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NAGE Health Care
- GERN Health Care
- Exchange
- NAGE Nasdaq
- GERN Nasdaq
- Market Cap
- NAGE 861.0M
- GERN 853.5M
- IPO Year
- NAGE N/A
- GERN 1996
- Fundamental
- Price
- NAGE $13.44
- GERN $1.51
- Analyst Decision
- NAGE Strong Buy
- GERN Buy
- Analyst Count
- NAGE 3
- GERN 7
- Target Price
- NAGE $16.67
- GERN $4.17
- AVG Volume (30 Days)
- NAGE 930.6K
- GERN 11.3M
- Earning Date
- NAGE 08-06-2025
- GERN 08-07-2025
- Dividend Yield
- NAGE N/A
- GERN N/A
- EPS Growth
- NAGE N/A
- GERN N/A
- EPS
- NAGE 0.18
- GERN N/A
- Revenue
- NAGE $107,925,000.00
- GERN $116,293,000.00
- Revenue This Year
- NAGE $26.21
- GERN $160.12
- Revenue Next Year
- NAGE $20.91
- GERN $55.01
- P/E Ratio
- NAGE $75.10
- GERN N/A
- Revenue Growth
- NAGE 29.77
- GERN 22264.04
- 52 Week Low
- NAGE $2.31
- GERN $1.17
- 52 Week High
- NAGE $14.49
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- NAGE N/A
- GERN 51.36
- Support Level
- NAGE N/A
- GERN $1.42
- Resistance Level
- NAGE N/A
- GERN $1.58
- Average True Range (ATR)
- NAGE 0.00
- GERN 0.10
- MACD
- NAGE 0.00
- GERN -0.01
- Stochastic Oscillator
- NAGE 0.00
- GERN 40.00
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.